semaglutide patent expiry india Generics to Launch in After Expiry, Prices May Drop 60% Semaglutide Patent Expiry: Indian Pharma

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging

Recent breakthroughs highlighted the dramatic effect of GLP-1RAs and related pharmaceuticals in reversing the effects imposed by metabolic syndrome on cardiovascular health.

In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals

Survey shows links to lower substance use and better impulse control.

Conclusions Consistent with clinical trials, real-world tirzepatide treatment was associated with greater 6-month weight reduction and more frequent achievement of weight-reduction targets and improvements in select cardiometabolic parameters than semaglutide among adults with obesity without diabetes

Introduction Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP1RA), is available in both parenteral and oral preparations